MANKIND PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,102 INR | +1.95% |
|
-1.25% | +6.05% |
| Jul. 09 | Mankind Pharma Reportedly to See Stake Sale Worth INR 7,630 Million through Block Deal | CI |
| Jul. 05 | Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids | RE |
Valuation
| Fiscal Period: March | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 842,335 | - | - |
| Enterprise Value (EV) 1 | 889,053 | 798,789 | 770,377 |
| P/E ratio | 48.3 x | 38.1 x | 32.1 x |
| Yield | 0.29% | 0.43% | 0.54% |
| Capitalization / Revenue | 8.92 x | 7.25 x | 6.4 x |
| EV / Revenue | 8.6 x | 6.87 x | 5.85 x |
| EV / EBITDA | 35.1 x | 27 x | 22.4 x |
| EV / FCF | 48.4 x | 43 x | 33.9 x |
| FCF Yield | 2.07% | 2.33% | 2.95% |
| Price to Book | 9.84 x | 7.28 x | 6.03 x |
| Nbr of stocks (in thousands) | 400,635 | - | - |
| Reference price 2 | 2,102 | 2,102 | 2,102 |
| Announcement Date | 5/15/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 87,494 | 103,348 | 116,241 | 131,584 |
| EBITDA 1 | - | 19,006 | 25,351 | 29,546 | 34,415 |
| EBIT 1 | - | 15,747 | 21,368 | 25,336 | 29,773 |
| Operating Margin | - | 18% | 20.68% | 21.8% | 22.63% |
| Earnings before Tax (EBT) 1 | - | 16,712 | 23,994 | 28,053 | 33,403 |
| Net income 1 | 14,335 | 12,819 | 19,129 | 22,085 | 26,282 |
| Net margin | - | 14.65% | 18.51% | 19% | 19.97% |
| EPS 2 | 35.78 | 32.00 | 47.68 | 55.17 | 65.59 |
| Free Cash Flow 1 | - | 10,243 | 18,371 | 18,592 | 22,712 |
| FCF margin | - | 11.71% | 17.78% | 15.99% | 17.26% |
| FCF Conversion (EBITDA) | - | 53.89% | 72.47% | 62.93% | 66% |
| FCF Conversion (Net income) | - | 79.91% | 96.04% | 84.19% | 86.42% |
| Dividend per Share 2 | - | - | 6.200 | 8.950 | 11.37 |
| Announcement Date | 8/1/22 | 5/30/23 | 5/15/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: Marzo | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|
| Net sales 1 | 25,786 | 26,998 | 24,214 | 24,228 | 29,134 |
| EBITDA 1 | 6,548 | 6,987 | 5,822 | 5,585 | 7,439 |
| EBIT 1 | 5,675 | 5,706 | 4,347 | 4,155 | 6,254 |
| Operating Margin | 22.01% | 21.13% | 17.95% | 17.15% | 21.47% |
| Earnings before Tax (EBT) 1 | 6,245 | 6,229 | 4,984 | 4,776 | 6,902 |
| Net income 1 | 4,869 | 5,176 | 4,194 | 3,823 | 5,654 |
| Net margin | 18.88% | 19.17% | 17.32% | 15.78% | 19.41% |
| EPS 2 | 12.14 | 11.00 | 9.867 | 9.350 | 13.90 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/2/23 | - | - | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: Marzo | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 32,600 | 43,546 | 71,959 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | 10,243 | 18,371 | 18,592 | 22,712 |
| ROE (net income / shareholders' equity) | - | 18.9% | 22.8% | 21.2% | 20.7% |
| ROA (Net income/ Total Assets) | - | 13.6% | 17.6% | 18% | 18.2% |
| Assets 1 | - | 94,317 | 108,394 | 122,797 | 144,463 |
| Book Value Per Share 2 | - | 186.0 | 234.0 | 289.0 | 349.0 |
| Cash Flow per Share 2 | - | 45.30 | 53.70 | 65.40 | 76.60 |
| Capex 1 | - | 7,890 | 3,153 | 4,952 | 5,256 |
| Capex / Sales | - | 9.02% | 3.05% | 4.26% | 3.99% |
| Announcement Date | 8/1/22 | 5/30/23 | 5/15/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
2,102
INR
Average target price
2,303
INR
Spread / Average Target
+9.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.05% | 9.9B | |
| +59.97% | 827B | |
| +38.38% | 634B | |
| -6.18% | 350B | |
| +15.61% | 319B | |
| +8.44% | 294B | |
| +12.68% | 240B | |
| +14.40% | 221B | |
| +0.04% | 219B | |
| +9.68% | 167B |
- Stock Market
- Equities
- MANKIND Stock
- Financials Mankind Pharma Limited
